A cardinal sin when researching neuropsin/KLK8: Thou shalt validate antibodies
- 18 July 2017
- journal article
- letter
- Published by Wiley in Alzheimer's & Dementia
- Vol. 13 (9), 1068-1069
- https://doi.org/10.1016/j.jalz.2016.12.016
Abstract
No abstract availableFunding Information
- National Institute on Aging
- Indiana Clinical and Translational Sciences Institute
- Indiana State Department of Health
This publication has 10 references indexed in Scilit:
- Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer’s DiseaseCurrent Alzheimer Research, 2017
- A proposal for validation of antibodiesNature Methods, 2016
- Kallikrein‐8 inhibition attenuates Alzheimer's disease pathology in miceAlzheimer's & Dementia, 2016
- Reproducibility crisis: Blame it on the antibodiesNature, 2015
- Evolution of the Plasma and Tissue Kallikreins, and Their Alternative Splicing IsoformsPLOS ONE, 2013
- Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementiaClinical Biochemistry, 2004
- Neuropsin (Opn5): a novel opsin identified in mammalian neural tissue1FEBS Letters, 2003
- Expression of the kallikrein gene family in normal and Alzheimer's disease brainNeuroReport, 2001
- Expression of a ubiquitous, cross-reactive homologue of the mouse beta-amyloid precursor protein (APP).Online Journal of Public Health Informatics, 1994
- Amyloid-like properties of peptides flanking the epitope of amyloid precursor protein-specific monoclonal antibody 22C11.Online Journal of Public Health Informatics, 1993